Management of older patients with frailty and acute myeloid leukaemia: A BSH good practice paper

Management of older patients with frailty and acute myeloid leukaemia: A British Society for Haematology good practice paper

Acute myeloid leukaemia (AML) is a highly heterogeneous haematopoietic stem cell malignant disorder and the most common malignant myeloid disorder in adults, with a median age of 70 years at presentation.1 Within this good practice paper we provide an update on developments specific to the older AML patient with frailty (a distinctive health state related to the aging process in which multiple body systems gradually lose their in-built reserves) where, historically, the potentially more effective intensive therapies have not been considered standard-of-care.


Read full Guideline